Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease (ACT-AD)
NCT04491006Phase 2Completed
- Sponsor
- LeonaBio
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of fosgonimeton in Alzheimer's disease (AD), sponsored by LeonaBio. Started Nov 2020; status: completed.
02
Drugs
fosgonimeton
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04491006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491006.